CPTR: Accelerating a New Paradigm of TB Treatment and
Diagnosis
CPTR is dedicated to accelerating the development of novel TB regimens and
diagnostics. In this video, TB survivors, thought leaders, and CPTR partners discuss
the nature and urgency of CPTR’s mission and ongoing efforts, including the ReSeqTB
Data Platform and analysis of past clinical trial data.
Watch the video »
REGISTER NOW — CPTR 2016 Workshop
Evolving TB Drug Regimen and Diagnostic
Development: Where Innovation Meets
Implementation

Date: April 4-7, 2016

Location: Omni Shoreham Hotel, Washington, DC
To view the agenda and to register, please visit the
registration page
Launch of ReSeqTB Data Platform for CPTR Rapid
DST Members and Data Contributors
The Relational Sequencing TB Consortia has launched the
ReSeqTB Data Platform, which is now available to data
contributors and Rapid DST Consortia members. This novel
Platform catalogs genotypic, phenotypic and related metadata
from M.tb strains. Access to such data will streamline the
development of clinically useful, WHO-endorsed in vitro
diagnostic assays for rapid drug susceptibility M.tb tests,
enabling quicker diagnosis of drug-resistant disease and more
appropriate use of treatment regimens. New analytic tools and
reports will be added within the coming months. The
ReSeqTB Data Platform is on track to launch globally in the
second half of 2016.
Read more
CPTR and WHO Partner to Improve Understanding of
Past Phase 3 TB Drug Trials
CPTR and the WHO Global TB Programme have partnered to
help maximize the knowledge and understanding gained from
completed Phase 3 TB drug clinical trials. The partnership will
bring together an expert steering committee to analyze three
contemporary Phase 3 trials (REMox TB, Rifaquin,
OFLOTUB), which tested the use of fluroquinolones to shorten
TB treatment. Among the areas to be studied is the
application of markers of treatment outcomes to inform
regimen selection and study design for future trials.
Read more
TB Alliance and Partners Announce Availability of
Appropriate, Child-friendly TB Medicines
TB Alliance, in partnership with UNITAID, USAID, and WHO
announced the availability of improved child-friendly, first-line
TB medicines. The improved treatments are the first to meet
the dosage guidelines set by the WHO in 2010. They are
dispersible and palatable, simple to administer and affordable.
Previously, treatment providers (often parents) routinely had
to crush or cut pills made for adults to concoct treatment for
children, approximating doses and risking the development of
drug-resistance. Efforts are now underway to ensure the
widespread adoption and use of these new cures.
Read more
TB and HIV: Combined Community Engagement
Forum
From September 27-29 in Johannesburg, South Africa,
community engagers in the TB and HIV research fields
convened for a first-of-its-kind joint Community Engagement
Forum. Participants shared tactics across fields and discussed
challenges to deepening and quantifying the impact of
community engagement work. By sharing learnings across
fields, sites, research networks and advocacy organizations,
the combined Community Engagement Forum helped build
stronger and more strategic communities of participatory and
stakeholder engagement practice.
Read more
Latest Progress Reports
Progress reports from CPTR’s Working Groups are published
on CPTRinitiative.org. Highlights in Q4 Progress include the
release of the “early adopter” version of the ReSeq TB Data
Platform, which includes more than 1500 isolates, with
thousands more to come. Additionally, the TB PACTS
platform for data sharing of completed Phase 3 clinical trials,
and the PBPK model to describe the distribution of TB drugs
through systemic blood into different lung compartments have
been operationalized. Other key progress areas include the
examination of all possible pncA polymorphisms and their
functional associations with pyrazimadase, completion of the
first round of Lights On/Off assay platform testing - the
encouraging results of which were presented at the 2015
IUATLD Annual Conference, and the launch of a new
collaboration between CPTR and WHO to conduct a modelbased meta-analysis of endpoints analyzed in completed
Phase 3 TB drug studies.
Click here for detailed progress reports from individual
working groups.
Questions or comments?